XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.

Core Viewpoint - XOMA Royalty Corporation has successfully completed its tender offer to acquire HilleVax, Inc. for $1.95 per share in cash, along with a contingent value right, resulting in HilleVax becoming a wholly owned subsidiary of XOMA Royalty [1][3]. Group 1: Tender Offer Details - The tender offer expired on September 15, 2025, with 39,214,689 shares of HilleVax common stock validly tendered, representing approximately 77.48% of the outstanding shares [2]. - All conditions of the tender offer were satisfied or waived, and XOMA Royalty accepted for payment all validly tendered shares immediately after the expiration [2]. Group 2: Merger and Delisting - Following the tender offer, XRA 4 Corp., a subsidiary of XOMA Royalty, merged with HilleVax, converting all non-tendered shares into the right to receive the offer price [3]. - HilleVax common stock will cease trading on Nasdaq and will be delisted and deregistered under the Securities Exchange Act of 1934 [3]. Group 3: Company Overview - XOMA Royalty is a biotechnology royalty aggregator that helps biotech companies by acquiring future economic rights associated with therapeutic candidates, providing non-dilutive funding for their development [5].